Interestingly, retrospective cohort studies found that men exposed to the mineralocorticoid receptor (MR)-antagonist spironolactone had a lower PCa risk [59,60], suggesting the tumor-promoting role of the MR. This evidence concerns the gene NR3C2 and neoplasm.